A major data correction published in Nature Medicine has updated the comprehensive Global Burden of Disease (GBD) assessment of substance use disorders affecting 204 countries from 1990 to 2023. The correction ensures that epidemiological estimates for amphetamine, cannabis, cocaine, and opioid use—among the world’s most prevalent drug disorders—now reflect verified data across three decades of global health surveillance.
- What the correction addresses
- Why global substance use data matters for public health
- Data verification and the GBD methodology
- Implications for substance use policy and clinical practice
- Frequently asked questions
- What is an “author correction” in a scientific journal, and does it mean the original study was wrong?
- How do researchers verify substance use prevalence data across 204 countries with varying data systems?
- Why are opioids, cannabis, amphetamines, and cocaine the focus of the GBD substance use assessment?
Key takeaways
- A major correction to the Global Burden of Disease Study now provides verified estimates of substance use disorders across 204 countries spanning 1990–2023
- The corrected data covers four primary substance classes: amphetamines, cannabis, cocaine, and opioids—the leading drugs of concern globally
- This update strengthens the evidence base for public health planning, drug policy, and clinical intervention strategies worldwide
- The correction demonstrates the importance of data transparency and verification in global health surveillance systems
Study at a Glance
| Source | Nature Medicine |
| Study type | Author Correction to Global Burden of Disease Study |
| Scope | 204 countries and territories |
| Time period | 1990–2023 (34 years) |
| Substances covered | Amphetamines, cannabis, cocaine, opioids |
Global Substance Use Disorder Burden: Key Data Points from Corrected GBD Study
Corrected estimates across major drug categories, 204 countries, 1990–2023
Source: Nature Medicine, 2026 | Georgian Medical Journal News
What the correction addresses
The Nature Medicine author correction updates a landmark Global Burden of Disease Study that quantified the health and social impact of substance use disorders worldwide. Corrections to GBD estimates are standard practice when data verification reveals inconsistencies or when improved methodologies allow for more precise measurement. The original study provided baseline estimates of disease burden (measured in disability-adjusted life years, or DALYs) attributable to amphetamine, cannabis, cocaine, and opioid use across all 204 countries and territories tracked by the World Health Organization.
This correction ensures that policymakers, clinicians, and public health officials relying on GBD data for resource allocation and intervention planning have access to the most accurate figures available. The Institute for Health Metrics and Evaluation (IHME), which maintains the GBD database, regularly releases corrections to maintain scientific integrity and accountability to the global health community.
Why global substance use data matters for public health
Substance use disorders represent a significant but often underestimated burden on health systems, criminal justice systems, and economies worldwide. The World Health Organization’s Global Status Report on Alcohol and Health and related substance surveillance efforts rely on standardized data from the GBD Study to guide international drug policy and treatment access recommendations. Corrected epidemiological estimates allow national health systems to better allocate resources for prevention, treatment, and harm reduction services.
The substances covered in the corrected GBD assessment—amphetamines, cannabis, cocaine, and opioids—span distinct epidemiological patterns across regions. Opioid use disorders predominate in high-income countries and increasingly in middle-income nations, while cannabis remains the most widely used illicit drug globally, and amphetamine-type stimulants drive burden in parts of East and Southeast Asia. Accurate country-level and regional data enables tailored policy responses.
Data verification and the GBD methodology
The Global Burden of Disease Study represents one of the most comprehensive efforts to quantify health loss from disease, injury, and risk factors across the globe. The IHME’s GBD framework integrates data from multiple sources: national health surveys, treatment registry records, published epidemiological studies, mortality registries, and expert elicitation. When inconsistencies emerge during data review or validation, corrections are issued to update the scientific record.
The substance use correction published in Nature Medicine reflects the standard peer-review and transparency processes that underpin the GBD initiative. This approach—acknowledging and correcting errors publicly—strengthens confidence in global health data systems. Clinicians and policymakers should view such corrections not as a loss of credibility but as evidence that the GBD system is functioning as designed: with robust quality checks and accountability.
Implications for substance use policy and clinical practice
Corrected prevalence and burden estimates from the Nature Medicine study inform multiple policy domains. Governments use GBD data to justify budget allocations for addiction treatment services, estimate unmet treatment needs, and design evidence-based drug strategies. Within clinical settings, accurate epidemiological context helps clinicians understand the population-level significance of substance use screening and treatment in their practice populations.
The update also supports cross-country comparisons of substance use burden, enabling health systems to benchmark their prevention and treatment efforts against international norms. For example, countries with disproportionately high opioid-related burden can prioritize medications for opioid use disorder (such as methadone and buprenorphine), while regions facing high cannabis-related harms can invest in early intervention and public education. Accurate data is the foundation for rational resource allocation in substance use public health.
The corrected Global Burden of Disease assessment provides verified epidemiological estimates of substance use disorders across amphetamines, cannabis, cocaine, and opioids in 204 countries and territories from 1990 to 2023, strengthening the evidence base for global drug policy and clinical practice.
— Nature Medicine, 16 June 2026 (Author Correction)
What this means
Frequently asked questions
What is an “author correction” in a scientific journal, and does it mean the original study was wrong?
An author correction is a formal revision of previously published data or methods, issued by the study authors or editors when errors or inconsistencies are identified during peer review or validation. A correction does not necessarily indicate that the entire study is invalid; rather, it updates specific data points, calculations, or interpretations to reflect verified information. For the Global Burden of Disease Study, corrections are routine quality assurance measures that ensure global health planners rely on the most accurate available estimates.
How do researchers verify substance use prevalence data across 204 countries with varying data systems?
The Global Burden of Disease Study uses a standardized methodology that integrates multiple data sources: national health surveys, treatment facility records, published epidemiological studies, and expert consultation. When data from different sources conflict, the GBD team applies statistical reconciliation techniques and, when necessary, issues corrections to reflect the most reliable evidence. This multi-source approach acknowledges that data quality varies by country and over time, and the correction process helps manage that heterogeneity.
Why are opioids, cannabis, amphetamines, and cocaine the focus of the GBD substance use assessment?
These four drug classes represent the largest burden of substance use disorders globally, accounting for the majority of treatment-seeking, disability, and mortality related to drug use. The GBD prioritizes tracking substances that cause the greatest public health impact. Other drugs are monitored in global surveillance systems, but opioids, cannabis, amphetamines, and cocaine are identified as the leading contributors to disease burden due to substance use, according to WHO epidemiological assessments.
The corrected GBD data published in Nature Medicine reflect the ongoing commitment of the global health community to transparency, data quality, and continuous improvement in substance use surveillance. As substance use patterns evolve—including the emergence of novel psychoactive substances and regional shifts in drug preferences—the GBD study continues to be updated with the most recent available evidence. Clinicians, policymakers, and researchers can access the full corrected dataset through the IHME GBD portal, supporting evidence-informed decisions in addiction medicine and drug policy across all 204 countries. This commitment to verified, transparent global health data strengthens the scientific foundation for responding to substance use as a public health priority.
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
